Company profile
Rapport Therapeutics, Inc. Common Stock
NASDAQ: RAPP · Healthcare · Biotechnology
PublicHQ Boston, DECIK 0002012593Reports USD
#1 of 1,422 Healthcare companies by revenue
EA Score
——FH 74DQ —GM —SS 51
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, Piotroski F
Methodology →Revenue TTM
$20.0M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$111.5M
Employees
84
as of 2026-08-09
Market cap
$2.2B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$111.5M-$111.5M2025
Operating income-$125.1M-$125.1M2025
Total assets$512.4M$512.4M2025
Liabilities$27.8M$27.8M2025
Equity$484.7M$484.7M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Rapport Therapeutics, Inc. Common Stock’s financial profile?
Rapport Therapeutics, Inc. Common Stock earned -$111.5M in FY2025 net income.
Peers · Healthcare
Sionna Therapeutics, Inc.——Biohaven Ltd.——Kailera Therapeutics, Inc.——Braveheart Bio, Inc.——Damora Therapeutics, Inc.——Generate Biomedicines, Inc.——Key facts
CEOAbraham N. Ceesay
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, DE
ExchangeNASDAQ: RAPP
Employees84
IPO date2024-06-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.